Grant Sweep

Consolidated research funding across disease areas and research fields — federal, foundation, state & industry sources in one filterable place.

← Back to opportunities
OpenU19Clinical trial: Optional / allowed

National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U19 Clinical Trial Optional)

National Institutes of Health (NIH) · NIH Institute/Center · PAR-25-353

Source: Grants.gov · View original posting ↗

Award
Amount not listed
Deadline
Oct 25, 2027
Letter of intent
Mechanism
U19
Duration
Expected awards
Funding cycle
Standard NIH dates
Open date
Jan 15, 2025
Total funding
Clinical trial
Optional / allowed
Established investigatorSmall businessGovernmentHigher educationNonprofitForeign entities

Research areas

Therapeutics & drug discovery

Auto-classified from the title and description (keyword-based) — may be imperfect.

Description

Reissue of PAR-20-119. This FOA encourages applications to advance the discovery, preclinical development, and proof of concept (PoC) testing of new, rationally based candidate agents and neurostimulation approaches to treat mental disorders, substance use disorders (SUDs) or alcohol use disorder (AUD), and to develop novel ligands and circuit-engagement devices as tools to further characterize existing or to validate new drug/device targets. Partnerships between academia and industry are strongly encouraged. This FOA supports a research program of multiple projects directed toward a specific major objective, basic theme or program goal, requiring a broadly based, multidisciplinary and often long-term approach. Projects seeking support for a discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his or her specific interest and competencies should consider the companion U01 FOA.

Data notes: award amount not published in the source feed; administering NIH institute could not be identified from the opportunity number.